| HOME >> BIOLOGY >> TECHNOLOGY |
Essentials and Research Specialties again achieved sales growth
exceeding long-term growth targets, and Research Biotech remained
on target to improve its growth rate. Third quarter gains for
three of the four focus areas in SAFC were in-line with first half
2008 performance, with a decline in SAFC's Pharma business
reflecting the impact of adverse economic conditions on
pharmaceutical spending;
-- Increasing reported and adjusted sales in CAPLA (Canada, Asia
Pacific and Latin America) markets by 8.8% and 6.8%, respectively,
in Q3 2008, with a Q3 2008 revenue contribution from these markets
at 20% of sales, consistent with the level achieved for all of
2007. Reported quarterly sales in our focus markets of India and
Brazil increased by 1% and 42%, respectively, with organic growth,
exclusive of currency impacts, of 10% and 23%, respectively. Sales
in China that had increased by 21% and 45% in the first and second
quarters of 2008, respectively, were impacted by government-imposed
operating restrictions related to the Olympic games in that
country, reducing third quarter 2008 sales by 9%, but with full
expectations for a recovery in the final quarter of 2008;
-- Increasing web-based sales through our award winning website by
17.6%. Web-based sales improved to 43% of worldwide Q3 2008
Research-based sales as e-commerce sales to international (Europe
and CAPLA) customers increased by 24.4%. E-commerce sales to U.S.
Research customers were 51% of total U.S. Research sales,
consistent with prior year-to-date levels;
-- Continuing our commitment to achieve $15 million in annual, pretax
'/>"/>
| SOURCE Sigma-Aldrich Copyright©2008 PR Newswire. All rights reserved |